Figure 3.
PPD promotes the endometrial receptivity possibly in hormone receptor dependent and independent manners. (A-C) mRNA-seq was performed to evaluate the differential expression genes in HESCs after treatment with or without PPD (40 µM) for 48 h. Gene Ontology (GO) enrichment and KEGG pathway enrichment analyzed have been shown. (D) qRT-PCR was used to evaluate the expressions of MMPs and collagens in HESCs after treatment with or without PPD (40 µM) for 48 h. (E) HESCs were treated by DMSO (1‰), or medroxyprogesterone acetate (MPA, 1 µM) combining with estradiol (E2, 1 nM), or PPD (40μM) for 48 h, and RT-PCR was used to measure the expression level of endometrial receptivity-related genes. (F) The mRNA level of endometrial receptivity-related genes in endometrium of EMs mice treated by control vehicle (5‰DMSO, every day), PPD (45 mg/kg, every 4 days), and GnRHa (0.5 µg, every day) (n=8). (G) PPI network of predicted sensory proteins of PPD (ESR1 and ESR2), PGR, endometrial receptivity-related molecules and collagens were obtained by STRING database and Cytoscape. (H) Top 15 predicted sensory proteins of PPD (get from SWISS Target Prediction website, showed in Table 1) involved in the regulation of endometrial receptivity and ECM remodeling, including AR, CYP19A1, HSD11B1, etc. (I) HESC were pre-treated with RU486 (1 nM or 10 nM) for 48h, then treated with or without PPD (40 µM) for 48h, or treated with DMSO (1 %) as control. Then, the mRNA level of PGR, IGFBP1 and LIF were analyzed by RT-PCR. Mean ± SEM, NS, no significant difference, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.